Evolent Health (NYSE:EVH) Given "Market Outperform" Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of Evolent Health (NYSE:EVH - Free Report) in a report published on Monday morning,Benzinga reports. JMP Securities currently has a $13.00 price objective on the technology company's stock.

EVH has been the subject of several other research reports. Citigroup dropped their price target on shares of Evolent Health from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, January 10th. JPMorgan Chase & Co. dropped their price target on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research note on Monday, March 10th. Stephens dropped their price target on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a research note on Tuesday, January 21st. Piper Sandler restated an "overweight" rating and issued a $16.00 price target (down previously from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Finally, Oppenheimer decreased their price objective on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, January 24th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Evolent Health has an average rating of "Buy" and a consensus target price of $17.71.

Evolent Health Trading Up 1.1 %

Evolent Health stock traded up $0.11 during trading on Monday, hitting $9.97. The company had a trading volume of 1,111,898 shares, compared to its average volume of 2,364,483. Evolent Health has a 1-year low of $8.35 and a 1-year high of $33.63. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The company's 50 day simple moving average is $9.47 and its 200-day simple moving average is $12.22. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -12.15 and a beta of 1.20.

Evolent Health (NYSE:EVH - Get Free Report) last posted its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The company had revenue of $646.54 million during the quarter, compared to analyst estimates of $650.92 million. As a group, analysts expect that Evolent Health will post 0.08 EPS for the current fiscal year.

Insider Activity

In other Evolent Health news, Director Diane Holder acquired 2,735 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were purchased at an average price of $9.33 per share, with a total value of $25,517.55. Following the completion of the acquisition, the director now directly owns 70,584 shares of the company's stock, valued at approximately $658,548.72. The trade was a 4.03 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Seth Blackley acquired 55,225 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the acquisition, the chief executive officer now directly owns 762,217 shares of the company's stock, valued at $6,867,575.17. This trade represents a 7.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 74,000 shares of company stock valued at $666,315. Company insiders own 1.60% of the company's stock.

Institutional Trading of Evolent Health

A number of institutional investors have recently bought and sold shares of EVH. Summit Creek Advisors LLC lifted its position in shares of Evolent Health by 0.8% in the fourth quarter. Summit Creek Advisors LLC now owns 202,114 shares of the technology company's stock valued at $2,274,000 after acquiring an additional 1,636 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in Evolent Health during the fourth quarter worth about $26,000. Parkside Financial Bank & Trust lifted its position in Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after buying an additional 2,358 shares during the period. Johnson Investment Counsel Inc. lifted its position in Evolent Health by 28.0% during the fourth quarter. Johnson Investment Counsel Inc. now owns 11,607 shares of the technology company's stock worth $131,000 after buying an additional 2,542 shares during the period. Finally, R Squared Ltd purchased a new position in Evolent Health during the fourth quarter worth about $31,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.